Antibody Technology Platforms

Background

We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART® and Fc Optimization platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes:

• multiple specificities;
• increased abilities to interact with the body’s immune system to fight tumors;
• capacity to bind more avidly to antigen targets;
• increased potency;
• reduced immunogenicity or
• the ability to target cancer cells that are resistant to standard treatments.

Moreover, these technology platforms are complementary and can be combined.

Our technology platforms include:

DART® and TRIDENT® Multi-Specific Platforms

Learn More: DART and TRIDENT Platforms

Fc Optimization Platform

Learn More: Fc Optimization Platform